Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Crispr Therapeutics Ag
(NQ:
CRSP
)
54.76
-0.71 (-1.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Crispr Therapeutics Ag
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
26
27
Next >
2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer
February 18, 2023
These two companies are on track to flourish through the end of the decade.
Via
The Motley Fool
Beat the Dow Jones With CRISPR Therapeutics Stock
February 17, 2023
If approved, CRISPR's first product may deliver blockbuster sales.
Via
The Motley Fool
These 2 Biotech Stocks Could Soar in the Next Bull Market
February 17, 2023
They're both at the cutting edge of gene-editing technology.
Via
The Motley Fool
3 Prime Healthcare Takeover Targets
February 14, 2023
These three companies are attractive targets for their potential.
Via
The Motley Fool
The Best Stocks To Invest $5,000 in Right Now
February 12, 2023
The time is right for each of these great stocks.
Via
The Motley Fool
These Cheap Growth Stocks Could Supercharge Your Portfolio
February 12, 2023
All of these players are cheap today considering their growth potential.
Via
The Motley Fool
Top CRISPR Stocks
February 11, 2023
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.
Via
Talk Markets
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
February 10, 2023
The gene-editing business has loads of potential, but is it enough to make you rich?
Via
The Motley Fool
Ready to Buy the Dip? Consider This Gene Editing Stock
February 06, 2023
CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back.
Via
The Motley Fool
Is Vertex Pharmaceuticals Stock a Buy Right Now?
February 10, 2023
The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains?
Via
The Motley Fool
2 Biotech Stocks That Could Make You Richer
February 09, 2023
Patience will pay off with these two stocks.
Via
The Motley Fool
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?
February 09, 2023
Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.
Via
The Motley Fool
Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.
February 09, 2023
CRISPR shares are ripe for a rebound after dropping 46% last year.
Via
The Motley Fool
1 Beaten-Down Stock That Has a Lot to Prove in 2023
February 08, 2023
This biotech looks like a high-risk, high-reward play.
Via
The Motley Fool
3 Top Stocks to Buy If There Is a Market Pullback
February 07, 2023
All three of these stocks performed well as the market fell in 2022.
Via
The Motley Fool
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
February 06, 2023
Cathie Wood is bullish about these stocks. And so are Wall Street analysts.
Via
The Motley Fool
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
3 No-Brainer Growth Stocks to Buy in 2023
February 03, 2023
These stocks all fell by double digits last year.
Via
The Motley Fool
Why Editas Medicine's Shares Jumped This Week
February 03, 2023
The gene-editing biotech's shares have had a strong two-week run.
Via
The Motley Fool
Is Editas Medicine Stock a Buy Now?
February 03, 2023
Layoffs and a thin clinical-stage pipeline aren't very encouraging.
Via
The Motley Fool
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later
February 02, 2023
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.
Via
InvestorPlace
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?
February 02, 2023
Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case?
Via
InvestorPlace
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock
February 01, 2023
Via
Benzinga
Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly'
February 01, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a
Via
Benzinga
3 Things About CRISPR Therapeutics That Smart Investors Know
January 31, 2023
The gene-therapy specialist's near-term outlook is quite bullish.
Via
The Motley Fool
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.
Via
InvestorPlace
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
January 27, 2023
These companies have the therapies to boost revenue for a decade.
Via
The Motley Fool
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
January 25, 2023
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
Via
InvestorPlace
3 Gene Editing Stocks With the Best Long-Term Potential
January 25, 2023
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space
Via
InvestorPlace
Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
January 22, 2023
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Via
The Motley Fool
< Previous
1
2
...
13
14
15
16
17
18
19
20
21
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.